First In Human Study Of Increasing Oral Doses Of PF-04634817

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The study will evaluate the hypothesis that at doses and plasma concentrations which affect pharmacodynamic markers of activity at the chemokine receptors, CCR2 and CCR5, the compound is safe and well tolerated. It will also evaluate the hypothesis that the pharmacokinetic profile is robust and consistent with a once or twice a day therapeutic administration.

Key facts

Study ID

NCT01098877

Run by

Pfizer

People needed

27

Starts

2010-04-01

Expected to finish

2010-09-01

Last updated by the study team

2010-10-13

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male or female (of non-child bearing potential) subjects between 18 and 55 years of age.
• Body mass index of 17.5 to 30.5 kg/m2 and total body weight > 50kg.

You may not qualify if…

• Evidence or history of any clinically significant disease.
• Treatment with an investigational drug within 30 days of study start
• Use of prescription and non-prescription medicines within 7 days of study start

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.